Last $192.68 USD
Change Today -3.35 / -1.71%
Volume 791.8K
As of 8:10 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

illumina inc (ILMN) Key Developments

Illumina Launches the NeoPrep Library Prep System

Illumina Inc. announced the launch of the NeoPrep Library Prep System, which greatly simplifies library preparation and delivers high-quality sequencing-ready libraries for next-generation sequencing (NGS). The newest addition to the Illumina portfolio of NGS solutions consists of a NeoPrep desktop instrument, disposable library cards, and reagents. Together with Illumina sequencers and the BaseSpace computing environment, the new system plays an integral role in providing NGS users with the easiest, most efficient and complete workflow. The NeoPrep System is the first commercially available product that performs library prep, quantification and normalization, in a single, self-contained instrument. Innovative digital microfluidics technology decreases hands-on time from several hours to 30 minutes. By precisely manipulating droplets within the tightly controlled library card environment, the system delivers reliable, high-quality DNA and RNA libraries from starting amounts 4 to 10 times lower than those required for equivalent manual assays. By creating 16 libraries per run, users can prepare up to 160 libraries per week, providing an affordable, walk-away solution that simplifies lab processes, and reduces the need for ancillary equipment and user-supplied reagents and consumables. The NeoPrep System is designed for use with the Illumina portfolio of library preparation kits, supporting the most commonly used NGS applications on all Illumina sequencing systems. Each kit includes the library card as well as all reagents required to create NeoPrep libraries. The NeoPrep System and NeoPrep versions of the TruSeq Nano DNA Kit and TruSeq Stranded mRNA Kit will begin shipping in March 2015. Additional library preparation products will become available later in the year, including NeoPrep versions of the TruSeq DNA PCR-Free Kit and other targeted resequencing kits.

Illumina Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 11:20 AM

Illumina Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 11:20 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Marc A. Stapley, Chief Financial Officer and Senior Vice President.

Illumina, Inc. Announces Retirement of Gerald Möller as Member of its Board of Directors

On January 29, 2015, Dr. Gerald Möller announced the board of directors of Illumina Inc. that he will retire as a member of the board of directors, effective immediately before the company’s 2015 annual meeting of stockholders.

Illumina Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 28, 2014; Provides Earnings Guidance for the Full Year of Fiscal 2015; Provides Tax Rate Guidance for the First Quarter of 2015

Illumina Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 28, 2014. For the quarter, the company announced total revenue of $512,379,000 compared to $387,326,000 for the same period a year ago. Income from operations was $202,883,000 compared to $73,784,000 for the same period a year ago. Income before income taxes was $192,061,000 compared to $120,369,000 for the same period a year ago. Net income was $153,280,000 compared to $80,661,000 for the same period a year ago. Net income per diluted share was $1.03 compared to $0.56 for the same period a year ago. Net cash provided by operating activities was $140,549,000 compared to $126,839,000 for the same period a year ago. Purchases of property and equipment were $34,832,000 compared to $27,310,000 for the same period a year ago. Free cash flow was $105,717,000 compared to $99,529,000 for the same period a year ago. Non-GAAP net income per share, diluted was $0.87 compared to $0.45 for the same period a year ago. Non-GAAP net income was $128,949,000 compared to $64,504,000 for the same period a year ago. Non-GAAP operating profit was $192,990,000 compared to $124,918,000 for the same period a year ago. Capital expenditures were $35 million, resulting in $106 million of free cash flow. For the full year, the company announced total revenue of $1,861,358,000 compared to $1,421,178,000 for the same period a year ago. Income from operations was $514,711,000 compared to $134,107,000 for the same period a year ago. Income before income taxes was $448,758,000 compared to $159,314,000 for the same period a year ago. Net income was $353,351,000 compared to $125,308,000 for the same period a year ago. Net income per diluted share was $2.37 compared to $0.90 for the same period a year ago. Net cash provided by operating activities was $501,271,000 compared to $386,421,000 for the same period a year ago. Purchases of property and equipment were $105,996,000 compared to $79,215,000 for the same period a year ago. Free cash flow was $395,275,000 compared to $307,206,000 for the same period a year ago. Non-GAAP net income per share, diluted was $2.74 compared to $1.80 for the same period a year ago. Non-GAAP net income was $407,217,000 compared to $249,663,000 for the same period a year ago. Non-GAAP operating profit was $686,275,000 compared to $462,229,000 for the same period a year ago. The company provided earnings guidance for the full year of fiscal 2015. For the fiscal 2015, the company is projecting approximately 20% revenue growth, assuming current currency exchange rates, and non-GAAP earnings per diluted share of $3.12 to $3.18. These projections assume full year non-GAAP gross margin of approximately 73%, and a pro forma tax rate of approximately 28%. The company also expects to report GAAP gross margin of 70.5% and GAAP diluted net income per share between $2.73 and $2.79. The company expects the first quarter of 2015 tax rate of approximately 29%.

Illumina Announces First Targeted Next-Generation Sequencing Solution for Forensic Genomics

Illumina Inc. announced the launch of the MiSeq FGx Forensic Genomics System, the first fully validated forensic next-generation sequencing (NGS) system, which simultaneously interrogates short tandem repeats (STR) and other valuable genetic markers, including single nucleotide polymorphisms (SNPs), to provide informative DNA profiles. The system enables more robust analysis of a broader range of genetic markers in a single workflow than previous technology allowed, supporting the reliable analysis of both routine and challenging forensic DNA samples. With the MiSeq FGx System, crime labs can now identify investigative leads from no suspect cases that may otherwise reach a dead end. Designed in collaboration with forensic genomics and human identification experts, the MiSeq FGx System leverages Illumina's sequencing by synthesis (SBS) chemistry, the most widely adopted NGS technology. Compatible with existing DNA databases, including the Combined DNA Index System (CODIS), the system can be used for criminal casework and in a range of situations, including mass disasters, missing persons, and unidentified human remains. Dense data sets, with powerful population statistics, can be generated for highly compromised samples, such as DNA degraded to less than 100 base pairs, aiding in the identification of the person whose DNA was obtained from the scene of a crime. The technology can also provide SNP-based physical information about bio-geographical ancestry and visible, physical traits, including hair and eye color. This information is often more reliable than eyewitness accounts and can be crucial in cases where traditional investigation does not identify a suspect. In addition to the MiSeq FGx DNA sequencer, the system includes the ForenSeqTM DNA Signature Prep Kit and ForenSeq Universal Analysis Software. This sample-to-answer solution will enable labs to maximize the information derived from a sample, generating more data from a single test than previously possible, and eliminating the need for multiple rounds of partial, iterative testing. Using low quantities of DNA (< 1 ng), the ForenSeq kit amplifies forensic targets via a streamlined workflow that maximizes the genetic information recovered from challenging samples and minimizes the potential for errors. Intuitive ForenSeq software facilitates the complete run setup, sample management, and analysis, and delivers reports on a stand-alone, dedicated server.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILMN:US $192.68 USD -3.35

ILMN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Avago Technologies Ltd $129.40 USD +1.18
Dr Reddy's Laboratories Ltd 3,442 INR +51.05
Sigma-Aldrich Corp $138.13 USD -0.07
Symrise AG €56.54 EUR +0.395
Waters Corp $120.24 USD +0.71
View Industry Companies
 

Industry Analysis

ILMN

Industry Average

Valuation ILMN Industry Range
Price/Earnings 82.6x
Price/Sales 15.0x
Price/Book 19.2x
Price/Cash Flow 71.8x
TEV/Sales 13.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ILLUMINA INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.